Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW 3,055.00
-35.00 (-1.13%)
At close: Sep 11, 2026
Cytogen Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 27,384 | 26,055 | 10,911 | 3,184 | 760.78 | 347.85 |
Revenue Growth | 31.63% | 138.80% | 242.63% | 318.57% | 118.71% | - |
Gross Profit Gross Profit Growth | 6,688 | 5,615 | 2,829 | 846.22 | 195.19 | 57.28 |
Operating Income Operating Income Growth | -6,555 | -8,163 | -10,666 | -11,792 | -11,497 | -12,861 |
Net Income Net Income Growth | -10,548 | -12,343 | -17,117 | -15,770 | -18,771 | -10,871 |
Earnings Per Share EPS Growth | -456.81 | -535.03 | -758.00 | -862.29 | -1063.00 | -642.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Liquid Biopsy Application Business Liquid Biopsy Application Business Growth | 12,913 | 12,423 | 5,120 | 866.06 | 615.15 | 347.85 |
Genome Technology Development and Analysis Services Genome Technology Development and Analysis Services Growth | 12,050 | 10,965 | 3,594 | - | - | - |
Toxicity and Molecular Diagnostic Tests Toxicity and Molecular Diagnostic Tests Growth | 2,422 | 2,667 | 2,196 | 2,318 | 145.63 | - |
Total Total Growth | 27,384 | 26,055 | 10,911 | 3,184 | 760.78 | 347.85 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 22,418 | 31,513 | 41,266 | 54,887 | 17,922 | 35,803 |
Total Debt Total Debt Growth | 14,265 | 16,279 | 14,872 | 17,576 | 26,424 | 24,624 |
Net Cash (Debt) Net Cash Growth | 8,152 | 15,233 | 26,395 | 37,311 | -8,502 | 11,179 |
Net Cash Growth | -58.66% | -42.29% | -29.26% | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 352.94 | 660.31 | 1168.28 | 2040.21 | -481.37 | 659.73 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -5,608 | -6,954 | -9,529 | -7,594 | -6,379 | -5,230 |
Capital Expenditures CapEx Growth | -1,752 | -1,970 | -1,007 | -2,498 | -645.8 | -1,219 |
Free Cash Flow Free Cash Flow Growth | -7,360 | -8,924 | -10,536 | -10,092 | -7,024 | -6,449 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 24.42% | 21.55% | 25.93% | 26.57% | 25.66% | 16.47% |
Operating Margin | -23.94% | -31.33% | -97.75% | -370.30% | -1511.28% | -3697.31% |
Pretax Margin | -40.57% | -49.71% | -164.35% | -508.09% | -2456.92% | -3830.07% |
Profit Margin | -38.52% | -47.37% | -156.88% | -495.22% | -2467.37% | -3125.13% |
FCF Margin | -26.88% | -34.25% | -96.56% | -316.91% | -923.33% | -1853.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 2.58 | 7.96 | 9.59 | 80.79 | 380.49 | 1022.63 |